All-trans retinoic acid potentiates the ability of interferon beta-lb to augment suppressor cell function in multiple sclerosis

Archives of Neurology

Volumn 55, Issue 3, 1998, Pages 315-321

  Qu, Zhi Xiang ^a   Dayal, Amit ^a   Jensen, Mark A ^a   Arnason, Barry G W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; RETINOIC ACID;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SUPPRESSOR CELL;

ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; HUMANS; IMMUNOSUPPRESSION; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-10; KILLER CELLS, NATURAL; LYMPHOTOXIN-ALPHA; MULTIPLE SCLEROSIS; TRETINOIN;

EID: 0031920180     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.3.315     Document Type: Article

References (46)

1. The INFB Multiple Sclerosis Study Group. Interferon-beta 1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
2. Arnason BGW. Interferon-beta in multiple sclerosis. Neurology. 1993;43:641-643.
3. Paty DW, Li DK, the UBC MS/MRI Study Group, and the INFB Multiple Sclerosis Study Group. Interferon-beta 1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
4. Jacobs LD, Cockfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
5. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
6. Arnason BGW, Reder AT. Interferons and multiple sclerosis. Clin Neuropharmacol. 1994;17:495-574.
7. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-1315.
8. Arnason BGW, Antel JP. Suppressor cell function in multiple sclerosis. Ann Immunol (Inst Pasteur). 1978;129C:159-170.
9. Antel JP, Arnason BGW, Medof ME. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol. 1979;5:338-342.
10. Antel JP, Bania MB, Reder A, Cashman N. Activated suppressor cell dysfunction in progressive multiple sclerosis. J Immunol. 1986;137:137-141.
11. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor function in progressive multiple sclerosis. Ann Neurol. 1990;27:207-210.
12. Panitch HS, Folus JS, Johnson KP. Activated suppressor cells inhibit synthesis of interferon-γ in patients with multiple sclerosis and normal subjects [abstract]. J Neuroimmunol. 1991;35(suppl 1):186.
13. Noronha A, Toscas A, Arnason BGW, Jensen M. IFN-beta augments in vivo suppressor function in MS. Neurology. 1994;44(suppl 2):A212.
14. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987;1:893-895.
15. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger the exacerbations? Acta Neurol Scand. 1988;78:318-323.
16. Lu C-Z, Jensen MA, Arnason BGW. Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol. 1993;46:123-128.
17. Dayal A, Jensen M, Lledo A, Arnason BGW. Interferon gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1B. Neurology. 1995;45:2173-2175.
18. Grant S, Bhalla K, Weinstein B, et al. Recombinant human interferon sensitizes resistant myeloid leukemic cells to induction of terminal differentiation. Biochem Biophys Res Commun. 1985;130:379-388.
19. Marth C, Daxenbiehler G, Dapunt O. Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst. 1986;77:1197-1202.
20. Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon a and their combination in five human transformed cell lines. Cancer Lett. 1991;57:223-227.
21. Bollag W, Peck R, Frey JR. Inhibition of proliferation by retinoids, cytokines and their combination in four human transformed epithelial cell lines. Cancer Lett. 1992;62:167-172.
22. Marth C, Widschwendter M, Daxenbichler G. Mechanism of synergistic action of all-trans- or 9-cis retinoic acid and interferons in breast cancer cells. J Steroid Biochem Mol Biol. 1993;47:123-126.
23. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W. Synergistic effect of retinoids and interferon a on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor cell lines. Int J Cancer. 1994;57:81-85.
24. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol. 1992;3:513-526.
25. Lippman SM, Glisson BS, Kavanagh JJ, et al. Retinoid acid and interferon combination studies in human cancer. Eur J Cancer. 1993;29A(suppl 5):S9-S13.
26. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-Retinoic acid and interferon A-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-240.
27. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al. 13-cis-Retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst. 1992;84:241-245.
28. Cantorna MT, Nashold FE, Hayes CE. In vitamin A deficiency multiple mechanisms establish a regulatory T helper cell imbalance with excess Th1 and insufficient Th2 function. J Immunol. 1994;152:1515-1522.
29. Cantorna MH, Nashold FE, Hayes CE. Vitamin A deficiency results in a priming environment conducive for Th1 cell development. Eur J Immunol. 1995;25:1673-1679.
30. Chun TY, Carman JA, Hayes CE. Retinoid repletion of vitamin A-deficient mice restores IgG responses. J Nutr. 1992;122:1062-1069.
31. Stosic-Grujicic S, Ejdus L. Modulation of in vitro T cell alloreactivity by synthetic retinoids. Immunopharmacology. 1994;27:87-92.
32. Massacesi L, Abbamondi AL, Giorgi C, Sarlo F, Lolli F, Amaducci L. Suppression of experimental allergic encephalomyelitis by retinoic acid. J Neurol Sci. 1987;80:55-64.
33. Massacesi L, Castigli E, Vergelli EM, et al. Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats. J Clin Invest. 1991;88:1331-1337.
34. Racke MK, Burnette D, Pak S-H, McFarlin DE, Scott DE. Retinoid treatment of experimental allergic encephalomyelitis: IL-4 production correlates with improved disease course. J Immunol. 1995;154:450-458.
35. Adamson PC, Bailey J, Pluda J, et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol. 1995;13:1238-1241.
36. McCall RB. Fundamental Statistics for Behavioral Sciences. San Diego, Calif: Harcourt Brace Jovanovich, 1986.
37. + mice. Science. 1992;256:1210-1213.
38. Abb J, Deinhardt F. Effects of retinoic acid on the human lymphocyte response to mitogens. Exp Cell Biol. 1980;48:169-179.
39. Dillehay DL, Cornay WJ III, Walia AS, Lamon EW. Effects of retinoids on human thymus-dependent and thymus-independent mitogenesis. Clin Immunol Immunopathol. 1989;50:100-108.
40. Abu-Khabar KS, Armstrong JA, Ho M. Type 1 interferons (IFN-α and -β) suppress cytotoxin (tumor necrosis factor-α and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J Leukoc Biol. 1992;52:165-172.
41. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF. Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol. 1991;147:1522-1529.
42. Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion: mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol. 1995;61:27-34.
43. Rudick RA, Ransohoff RM, Peppier R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol. 1996;40:618-627.
44. Noronha A, Toscas A, Jensen MA. Contrasting effects of alpha, beta and gamma interferons on nonspecific suppressor cell functions in multiple sclerosis. Ann Neurol. 1992;31:103-106.
45. Kolla V, Lindner DJ, Weihua X, Borden EC, Kalvakolanu DV. Modulation of interferon (IFN)-inducible gene expression by retinoic acid: up-regulation of STAT 1 protein in IFN-unresponsive cells. J Biol Chem. 1996;271:10508-10514.
46. Matikainen S, Ronni T, Hurme M, Pine R, Julkunen I. Retinoid acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood. 1996;88:114-123.